Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $290,403,000 | $232,261,000 | $176,954,000 | $140,800,000 |
| % Growth | 25% | 31.3% | 25.7% | – |
| Cost of Goods Sold | $44,522,000 | $35,765,000 | $28,448,000 | $23,658,000 |
| Gross Profit | $245,881,000 | $196,496,000 | $148,506,000 | $117,142,000 |
| % Margin | 84.7% | 84.6% | 83.9% | 83.2% |
| R&D Expenses | $48,062,000 | $32,443,000 | $24,047,000 | $17,772,000 |
| G&A Expenses | $5,276,000 | $4,855,000 | $4,467,000 | $4,050,000 |
| SG&A Expenses | $67,377,000 | $61,598,000 | $50,684,000 | $41,058,000 |
| Sales & Mktg Exp. | $62,101,000 | $56,743,000 | $46,217,000 | $37,008,000 |
| Other Operating Expenses | $2,103,000 | -$119,000 | -$1,034,000 | -$332,000 |
| Operating Expenses | $117,542,000 | $93,922,000 | $73,697,000 | $58,498,000 |
| Operating Income | $128,339,000 | $102,574,000 | $74,809,000 | $58,644,000 |
| % Margin | 44.2% | 44.2% | 42.3% | 41.7% |
| Other Income/Exp. Net | -$1,148,000 | $2,100,000 | -$5,558,000 | $436,000 |
| Pre-Tax Income | $127,191,000 | $104,674,000 | $69,251,000 | $59,080,000 |
| Tax Expense | $26,203,000 | $20,991,000 | $13,537,000 | $11,323,000 |
| Net Income | $100,988,000 | $83,683,000 | $55,525,000 | $47,757,000 |
| % Margin | 34.8% | 36% | 31.4% | 33.9% |
| EPS | 22.68 | 9.34 | 12.26 | 10.4 |
| % Growth | 142.8% | -23.8% | 17.9% | – |
| EPS Diluted | 22.64 | 9.31 | 12.22 | 10.37 |
| Weighted Avg Shares Out | 4,453,670 | 4,494,253 | 4,530,600 | 4,593,200 |
| Weighted Avg Shares Out Dil | 4,460,500 | 4,494,800 | 4,544,600 | 4,605,304 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,838,000 | $1,069,000 | $239,000 | $231,000 |
| Interest Expense | $1,640,000 | $739,000 | $378,000 | $289,000 |
| Depreciation & Amortization | $8,545,000 | $5,825,000 | $5,306,000 | $5,311,000 |
| EBITDA | $137,376,000 | $111,041,000 | $76,802,000 | $64,826,000 |
| % Margin | 47.3% | 47.8% | 43.4% | 46% |